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ABSTRACT
Introduction: Laser photocoagulation has been
the standard treatment for diabetic macular
edema (DME) and proliferative diabetic
retinopathy (PDR) for several decades. The dis-
covery of vascular endothelial growth factor
(VEGF) and the subsequent determination of its
critical role in the development DME and PDR
has led to the development of VEGF inhibitory
drugs. Ranibizumab was the first anti-VEGF
drug approved for the treatment of both DME
and diabetic retinopathy in eyes with DME.
Methods: Medline searches with the keywords
‘‘ranibizumab,’’ ‘‘diabetic macular edema,’’ and
‘‘proliferative diabetic retinopathy’’ were per-
formed to identify pertinent pre-clinical studies
and clinical trials. Top-line data, with emphasis
on pivotal trials, was identified and incorpo-
rated into this manuscript. Findings from small
uncontrolled trials were generally not used
unless they filled important gaps in our under-
standing of anti-VEGF therapy.
Results: Ranibizumab is a recombinant
humanized antibody fragment that binds all
isoforms of VEGF-A with high affinity. Three
parallel lines of clinical research have produced
level I evidence supporting the superiority of
ranibizumab over laser photocoagulation for
the treatment of DME. Regular injections also
lead to improvement in diabetic retinopathy
severity scores in a large minority of eyes.
Ranibizumab is effective for PDR and produces
less visual field loss than laser photocoagula-
tion. It has an excellent safety profile, with low
incidence of ocular and systemic adverse events.
Conclusions: Ranibizumab has become a fre-
quently used first-line therapy for the treatment
of DME. Emerging data suggest that it may
become an important treatment for DR and
PDR.
Keywords: Anti-VEGF; Diabetic macular
edema; Diabetic retinopathy; Proliferative
diabetic retinopathy; Ranibizumab; Vascular
endothelial growth factor
INTRODUCTION
Diabetes mellitus (DM) is responsible for more
vision loss among working-aged individuals in
industrialized nations than any other condition
[1, 2]. Diabetes affects nearly every part of the
visual system, but most vision loss results from
complications of diabetic retinopathy (DR).
Improved access to care and newly developed
drugs are reducing the prevalence of DR within
diabetic populations, but because the incidence
Enhanced content To view enhanced content for this
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of both type 1 and type 2 DM is increasing
[3, 4], the total number of patients with DR is
rapidly rising throughout the world. The
resulting demand for endocrinology and oph-
thalmology services is straining healthcare
delivery systems [5] and threatens to increase
the number of patients with significant vision
loss and blindness.
The lack of effective treatment for DR
throughout much of the twentieth century
meant that many patients with DR suffered
complete loss of sight. Laser photocoagulation
was introduced in the 1960s and rapidly became
the standard of care for the treatment of dia-
betic macular edema (DME) [6] and proliferative
diabetic retinopathy (PDR) [7]. Laser therapy
frequently delayed or prevented vision loss, but
significant improvement in visual acuity was
uncommon [8]. Only with the development
and introduction of intraocular pharmacother-
apy have patients been able to reasonably hope
for recovery of pre-existing visual acuity.
Ranibizumab (Lucentis, Genentech, South
San Francisco, CA, USA/Roche, Basel, Switzer-
land), a recombinant humanized antibody
fragment that binds vascular endothelial
growth factor (VEGF), was the first drug
approved for the treatment of both DME and
DR. This paper will focus on the clinical use of
ranibizumab to treat vision-threatening com-
plications of DR. This article is based on previ-
ously conducted studies and does not involve
any new studies of human or animal subjects
performed by any of the authors.
DEVELOPMENT OF RANIBIZUMAB
Michaelson [9] first proposed the notion that a
soluble vasoproliferative factor produced neo-
vascularization in eyes with advanced DR, and
Folkman [10] subsequently linked tumor
growth to angiogenesis. The vasopermeability
factor (VPF) was discovered in 1983 [11], and
the vascular endothelial growth factor, deter-
mined by protein sequencing analysis to be
identical to VPF, was discovered independently
by Ferrara and Connolly [12, 13]. Researchers
demonstrated that vascular endothelial growth
factor concentrations were elevated in the
vitreous of eyes with several chorioretinal vas-
cular conditions, including DME and PDR [14].
Injecting VEGF into rat eyes was found to pro-
duce retinal hemorrhages and vascular changes
similar to those seen in patients with DR [15],
and was able to be prevented with the co-ad-
ministration of a VEGF trap [16]. Injecting
VEGF into monkey eyes produced neovascular-
ization of the iris [17].
Several different bioengineering strategies
have been used to develop VEGF-binding drugs.
Scientists at Genentech produced bevacizumab,
a full-length, recombinant, humanized, murine
anti-VEGF antibody for the intravenous treat-
ment of advanced solid malignancies. For sev-
eral reasons, including concerns over a limited
ability to penetrate the inner layers of the
retina, possible production of an inflammatory
response within the eye, and prolonged serum
half-life, bevacizumab was not deemed appro-
priate for chorioretinal vascular conditions, so
ranibizumab was developed exclusively for
intraocular use [18].
Ranibizumab has a molecular weight of
48 kDa, approximately one-third that of a
full-length antibody (Table 1). Six amino acids
in the Fab originally used to construct beva-
cizumab were substituted to produce the affin-
ity-enhanced ranibizumab molecule. Despite
having only one VEGF binding site, ranibizu-
mab is 5 to 20 times as potent as bevacizumab
(two binding sites) when evaluated in similar
bioassays [18]. Ranibizumab possesses a high
binding affinity for VEGF165 (46–172 pM)
[19, 20].
Research has shown that after the intravit-
real injection of ranibizumab into monkey eyes,
drug penetration of the outer retina occurs
quickly, with resulting tissue concentrations
approximately one-third of those seen in the
vitreous [21]. Various studies suggest that the
intravitreal half-life of ranibizumab ranges from
2.8 to 2.88 days [22, 23] in rabbits and 2.6 to
3.2 days in monkeys [21, 24]. Estimates of
ranibizumab’s intraocular half-life in human
eyes vary from 7.19 days (based on anterior
segment samples) [25] to 9 days (population
pharmacokinetic study) [26]. Ranibizumab is
believed to pass from the eye into the systemic
circulation without undergoing metabolic
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changes. Because of its short serum half-life of
2 h, ranibizumab does not diminish serum
VEGF concentrations [27] before being removed
from the body by ultrafiltration through the
kidneys.
Figure 1 presents optical coherence tomog-
raphy images illustrating improvements in a
patient receiving monthly ranibizumab
injections.
CLINICAL TRIALS FOR DIABETIC
MACULAR EDEMA
Pilot Trials
Ranibizumab entered clinical trials for neovas-
cular age-related macular degeneration (nAMD)
in 2000, an investigative sequence that culmi-
nated with the publication of the ANCHOR [28]
and MARINA [29] trials in 2006 and approval by
the US Food and Drug Administration (FDA) in
the same year. At approximately the same time,
two small pilot studies explored the safety and
efficacy of ranibizumab in patients with DME.
In the READ-1 study [30], ten patients with
chronic DME received intravitreal injections of
0.5 mg ranibizumab at baseline and 1, 2, 4, and
6 months. By the 7-month endpoint, mean
best-corrected visual acuity (BCVA) had
improved by ?12.3 letters. Mean macular vol-
ume improved from 9.22 to 7.47 mm2 (77%
reduction in excess volume) and mean foveal
thickness improved from 503 lm to 257 lm
(85% reduction in excess thickness). The other
study enrolled ten patients in an open-label,
dose-escalation protocol [31]. Patients received
low-dose (0.3 mg) or high-dose (0.5 mg) ranibi-
zumab at baseline, and 1 and 2 months. The
mean improvements in BCVA and macular
thickness at 3 months for the 0.3-mg and
0.5-mg arms were ?12 and ?7.8 letters and
-45.3 and -197.8 lm, respectively. Improve-
ments in BCVA decreased slightly between 3
and 6 months.
These studies demonstrated that DME
responds well to ranibizumab, but they failed to
demonstrate superiority of either the 0.3-mg or
0.5-mg dose and suggested that 2-month injec-
tion intervals may be sufficient. Subsequent
development of ranibizumab for DME pro-
ceeded along three research lines: READ-2/RISE
and RIDE (Genentech-sponsored in the USA
and South America); RESOLVE/RESTORE (No-
vartis-sponsored ex-US); and Diabetic
Retinopathy Clinical Research Network
(DRCR.net) Protocol I (National Eye Insti-
tute-sponsored). Table 2 lists the important DR
clinical trials with ranibizumab and details their
key findings.
READ/RISE and RIDE
Following successful completion of the READ-1
trial, the phase II READ-2 trial was performed at
14 sites [32]. This prospective controlled trial
randomized 126 patients to receive 0.5 mg
ranibizumab at baseline and 1, 3, and 5 months
(group 1), laser at baseline and at month 3 if
needed (group 2), and ranibizumab combined
with laser at baseline and month 3 if needed
Table 1 Some of the important biochemical and pharmacokinetic characteristics of ranibizumab
Important biochemical and pharmacokinetic characteristics of ranibizumab
Description Recombinant humanized murine antibody
fragment speciﬁc to VEGF-A
Molecular weight 48 kDa
Isoforms and families bound All isoforms of VEGF-A
Binding afﬁnity for VEGF165 46–179 (pM)
Intravitreal half-life 7.1–9 days
Serum half-life 2 h
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(group 3). At the 6-month primary endpoint,
the improvement in BCVA for group 1 was sig-
nificantly greater than for group 2 (?7.24 vs.
-0.43 letters; P = 0.0001) but not significantly
different from that of group 3 (?3.8 letters).
Fifteen-letter improvement in BCVA was
achieved by 22%, 0%, and 8%, and excess
macular thickness was reduced in 50%, 33%,
and 45%, respectively.
Between months 6 and 24, all patients
became eligible to receive ranibizumab injec-
tions every 2 months. At 24 months, mean
improvements in BCVA were ?7.7, ?5.1, and
?6.8 letters, and the proportions of patients
improving by 15 letters were 24%, 18%, and
26%. Mean central subfield thickness (CST)
measurements were 340, 286, and 258 lm. By
month 24, mean visual acuity improvement
experienced by the cohort initially randomized
to laser approached that of the ranibizumab
group, but the excess macula thickness in the
ranibizumab monotherapy group indicated that
these patients were probably under-treated [33].
Fig. 1 Optical coherence tomography scans through the
macula of a 68-year-old woman with type 2 diabetes
mellitus for 15 years. Her visual acuity at the baseline
examination (top row) measured 20/40 -2, and the central
subﬁeld thickness measured 414 lm. After 6 monthly
injections of 0.3 mg ranibizumab (middle row), her visual
acuity had improved to 20/40 ? 2 and the central subﬁeld
thickness had improved to 350 lm. Monthly injections
were continued, and by 14 months (bottom row), the
macular edema had largely resolved except for a small
residual cystoid space. At this time, her visual acuity
measured 20/30 and central subﬁeld thickness measured
260 lm
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1. More RAN patients than sham had 3-line improvement in BCVA (33.6–45.7%
vs. 12.3–18.1%)
2. RAN patients had greater improvement in mean BCVA compared to sham
(?10.9 to ?12.5 letters vs. ?2.3 to ?3 letters)
3. RAN patients had greater improvement in central foveal thickness compared to
sham (-250.6 to -270.7 lm vs. -125.8 to -133.4 lm)
4. RAN patients had signiﬁcant improvement in diabetic retinopathy severity
scores
At 36 months:
1. For RAN patients, BCVA and central foveal thickness similar to 24 months
2. Sham patients crossed over to RAN, and BCVA improved by approximately ?2







0.5 mg ? laser
Laser
At 12 months:
1. Mean BCVA improvements were ?6.1, ?5.9, and ?0.8 letters
2. Mean improvements in macular thickness were -118.7, -128.3, and -61.3 lm
At 36 months:
1. Laser arm crossed over to RAN at 12 months; BCVA caught up to







0.5 mg ? laser
RAN
0.5 mg ? deferred
laser
IVT 4 mg ? laser
Laser
At 12 months:
1. Improvements in mean BCVA were ?9, ?9, ?4, and ?3 letters
At 36 months:
1. Patients treated with RAN ? deferred laser improved by 2.9 letters more than
RAN ? prompt laser
2. Compared to patients in RAN ? prompt laser, patients in RAN ? deferred










1. In eyes with baseline VA of 20/32 to 20/40, mean BCVA improved by ?7.8,
?6.8, and ?8.6 letters
2. In eyes with baseline VA of 20/50 or worse, mean BCVA improved by ?18.1,
?13.3, and ?16.1 letters
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At 24 months, the protocol was amended a
second time to allow all patients to receive
monthly pro re nata (PRN) ranibizumab in year
3. From the 24-month to the 36-month visits,
patients had mean BCVA gains of ?3.1, -1.6,
and ?2.0 letters. An average of 5.4, 2.3, and 3.2
ranibizumab injections were administered dur-
ing the third year [34].
A higher dose of ranibizumab (2.0 mg) had
been tested during the exploratory dosing nAMD
trials, but it was quickly abandoned because of its
high viscosity and tendency to cause inflamma-
tion. Several years later, however, the 2.0-mg
dose was re-evaluated in the HARBOR trial [35]
for nAMD and the READ-3 trial [36] for DME.
Patients with DME received either the 2.0-mg or
the 0.5-mg ranibizumab dose monthly for
6 months, followed by monthly PRN injections
through month 12. Patients receiving 0.5 mg
experienced a non-statistically significant
greater improvement in BCVA (?9.34 letters vs.
?7.04 letters), and more patients receiving the
2.0-mgdosedied frommyocardial infarction (4%
vs. 1%). Because neither the READ-3 nor HAR-
BOR trial showed that high-dose ranibizumab
offered a clinical advantage, further develop-
ment of the 2.0-mg dose was halted. The READ
trials suggested that monthly ranibizumab was
needed to produce optimal visual acuity results,
but that higher doses provided no added benefit
and might actually increase the risk of serious
systemic adverse events.
As a result, the multi-center, double-masked
parallel 3-year phase III RISE and RIDE regis-
tration trials compared the efficacy of low-
er-dose (0.3 mg and 0.5 mg) monthly
ranibizumab against sham for patients with
center-involving DME [37]. Seven hundred fif-
ty-nine patients were randomized to one of
three treatment arms: monthly 0.3 mg ranibi-
zumab, monthly 0.5 mg ranibizumab, or sham.
Patients were eligible for rescue laser photoco-
agulation at 3 months if the central retinal
thickness (CRT) was[250 lm and if the change
in CRT following the previous injection was
\50 lm. The primary endpoint was the pro-
portion of subjects improving by at least ?15
letters at 24 months, and secondary endpoints
included improvement in BCVA, improvement
in macular thickness, and safety measures.
At the 24-month primary endpoint, the
proportion of patients who improved by at least
?15 letters was significantly greater in patients
receiving 0.3 mg and 0.5 mg ranibizumab than
in patients who received sham injections in
both RISE (44.8%, 39.2%, and 18.1%) and RIDE
(33.6%, 45.7%, and 12.3%). Mean improvement
in BCVA was also greater in the groups receiving
ranibizumab in both RISE (?12.5, ?11.9, and
?2.6 letters) and RIDE (?12.0, ?10.9, and ?2.3
letters), as were corresponding mean improve-
ments in central foveal thickness (CFT) in RISE
(-250.6 lm, -253.1 lm, and -133.4 lm) and
RIDE (-259.8 lm, -270.7 lm, and -125.8 lm).
Fewer patients receiving ranibizumab required
rescue laser (means of 0.3 to 0.8) compared to
those randomized to sham injections (means of
1.8 and 1.6). In the groups treated with 0.3 mg
ranibizumab, 37.2% experienced a two-step or
greater improvement in diabetic retinopathy
severity score (DRSS), and 13.2% experienced a














1. Mean BCVA improved by ?2.8 and ?0.2 letters
2. Mean BCVA area under the curve: difference of ?4.2 letters (P\0.001)
3. Change in threshold visual ﬁeld sensitivity (-23 vs. -422 dB; P\0.001)
AFL aﬂibercept, BCVA best-corrected visual acuity, BEV bevacizumab, DRCR.net Diabetic Retinopathy Clinical Research
Network, IVT intravitreal triamcinolone acetonide, RAN ranibizumab, VA visual acuity
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The median DRSS remained stable at moder-
ately severe NPDR in the sham groups, whereas
scores improved from moderately severe to mild
NPDR in the ranibizumab groups. Fewer patients
receiving ranibizumab experienced a two-step
worsening in the DRSS (1.7% to 2.1% vs. 9.6% in
sham), and fewer ranibizumab patients devel-
oped vitreous hemorrhage. Since changes in
BCVA were the same for patients receiving the
0.3-mgand0.5-mgdoses of ranibizumab, and the
incidence of several categories of adverse events
including central nervous system and cere-
brovascular hemorrhage appeared to increase in
a dose-dependent fashion (although the num-
bers were low), Genentech recommended the
0.3-mg dose for approval. The US FDA ultimately
approved the use of 0.3 mg ranibizumab for DME
on August 10, 2012. The label was subsequently
expanded (2015) to include the treatment of
diabetic retinopathy (NPDR and PDR) in patients
with DME.
During year 3, patients continued receiving
monthly ranibizumab injections, and those
randomized to sham were eligible to receive
monthly 0.5 mg ranibizumab [38]. From the
24-month to the 36-month visits, patients in the
ranibizumab arms had stable BCVA, whereas
those in the sham arms improved to ?4.3 (RISE)
and ?4.7 (RIDE) letters above baseline.
After the 36-month visit, 500 patients were
followed in the extension study for a mean of
14.1 months [39]. All patients were eligible to
receive monthly PRN 0.5 mg ranibizumab if
DME was identified by the investigator or BCVA
worsened by at least five letters compared to
month 36. Patients received a mean of 4.5
injections (annualized: 3.8), but 24.2% of
patients did not require any injections. BCVA
remained stable in all groups and mean CFT
increased slightly. Few patients developed PDR,
and those originally randomized to ranibizu-
mab had a lower overall rate of progression to
PDR than those originally randomized to sham.
RESOLVE/RESTORE
The phase II RESOLVE and phase III RESTORE
trials that were performed in Europe, Asia, and
Australia served as the basis for regulatory
approval of ranibizumab in these regions for
treatment of DME. In the 12-month RESOLVE
trial, 151 patients were randomized to receive
monthly 0.3 mg ranibizumab, 0.5 mg ranibizu-
mab, or sham injections [40]. After 1 month,
the drug dose could be doubled if the CRT was
greater than 300 lm, or greater than 225 lm if
the CRT decreased by \50 lm following the
previous injection. At 3 months, patients
received ranibizumab injections or sham injec-
tions on a monthly PRN basis, and all were eli-
gible for rescue laser photocoagulation. At the
12-month primary temporal endpoint, mean
BCVA improved by ?10.3 letters in the pooled
ranibizumab groups but declined by -1.4 letters
in the sham group. BCVA gains of ?2 lines and
?3 lines were achieved by 60.8% and 32.4% of
ranibizumab-treated eyes, but only 18.4% and
10.2% of sham-treated eyes, respectively. Mean
improvements in CRT were -194.2 lm for the
pooled ranibizumab groups and -48.4 lm for
the sham group. Eighty-six percent of all eyes
received a ranibizumab dose of 0.5 to 1.0 mg at
some point during the trial. The mean number
of administered injections was 10.2, and only
4.9% of ranibizumab treated-eyes (compared to
34.7% of sham eyes) required rescue laser.
Since nearly all patients in the RESOLVE trial
eventually received a ranibizumab dose of at
least 0.5 mg, only the larger (0.5 mg) dose was
included in the design of the RESTORE trial.
RESTORE was the multi-center (73 sites) phase
III ranibizumab registration trial for the Eastern
Hemisphere [41]. Three hundred forty-five
patients were randomized to receive
ranibizumab ? sham laser, ranibizumab ? laser,
or sham injections ? laser. Ranibizumab injec-
tions were administered monthly for three
months, then monthly PRN; laser was per-
formed at baseline and then every 3 months
PRN. The trial’s primary objective was to
demonstrate superior mean BCVA improve-
ment at 12 months in patients treated with
ranibizumab monotherapy or ranibizumab
combined with laser compared to laser
monotherapy. Secondary objectives included
the proportions of patients achieving BCVA of
at least 73 letters (20/40), the time course of the
change in mean BCVA and CRT,
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patient-reported outcomes relative to laser
photocoagulation, and safety measures.
At the 12-month primary endpoint, patients
in the ranibizumab monotherapy,
ranibizumab ? laser, and sham/laser groups
demonstrated improvements in mean BCVA
(?6.1, ?5.9, and ?0.8 letters), BCVA score[73
letters (53.0%, 44.9%, and 23.6%) and CRT
(-118.7 lm, -128.3 lm, and -61.3 lm).
Health-related quality-of-life scores (measured
by the 25-item National Eye Institute Visual
Function Questionnaire [NEI VFQ-25])
improved more in the ranibizumab monother-
apy and ranibizumab ? laser groups than in the
sham/laser group (P\0.05 for each). Subgroup
analyses showed that patients with baseline
BCVA of C73 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters or CRT
\400 lm achieved final BCVA that was as good
with laser as with ranibizumab. Patients
received a mean of seven ranibizumab/sham
injections.
After the 12-month primary endpoint, 240
patients were enrolled in the 24-month exten-
sion trial. All patients were eligible to receive
0.5 mg ranibizumab according to BCVA and
disease progression criteria, and at the investi-
gators’ discretion. Additional laser photocoag-
ulation was allowed according to ETDRS
guidelines. At the pre-planned 24-month
interim analysis, patients who originally
received ranibizumab monotherapy and
ranibizumab ? laser maintained improvements
in mean BCVA (?7.9 letters, ?6.7 letters), CRT
(-140.6 lm, -133.0 lm), and NEI VFQ-25
composite scores (5.6, 5.8) [42]. Between the 12-
and 24-month examinations, patients originally
treated with sham/laser experienced significant
improvement in these measures (?5.4 letters,
-126.6 lm, 4.3) after receiving ranibizumab.
Similar numbers of injections were performed
in each treatment arm (3.9, 3.5, and 4.1).
Most of the patients (208; 86.7%) were rolled
into and completed the 24-month extension
study. While patients received as-needed rani-
bizumab injections during the period between
the 12- and 36-month examinations, BCVA and
CRT were maintained [43]. At 36 months,
improvements in BCVA were ?8.0 letters
(ranibizumab monotherapy), ?6.7 letters
(ranibizumab ? previous laser), and ?6.0 letters
(original sham/laser arm). The mean numbers
of injections over the final 2 years varied from
6.0 to 6.8 for each of the three treatment arms.
DRCR.net Protocol I
The DRCR.net Protocol I trial provided the first
level I evidence that supported the use of rani-
bizumab as primary treatment for DME. Proto-
col I was a 5-year multi-center study that
randomized 854 eyes with center-involving
DME to receive 0.5 mg ranibizumab with
prompt macular laser photocoagulation, 0.5 mg
ranibizumab with deferred laser (for at least
6 months), intravitreal triamcinolone with
prompt laser, or sham injections with prompt
laser [44]. Patients received ranibizumab injec-
tions during the first year according to the 4:2:7
rule—four monthly injections, followed by two
additional injections if fluid persisted, followed
by seven visits during which the drug could be
administered at the investigator’s discretion if
insufficient improvement was noted. Laser
photocoagulation of the macula and intravit-
real triamcinolone (4 mg) injections could be
repeated every 16 weeks and 13 weeks, respec-
tively, as needed. Patients randomized to the
ranibizumab ? deferred laser group were not
required to receive laser treatment at 6 months
and beyond if the macula was dry.
At the 12-month examination, mean
improvements in BCVA in the ranibizumab ?
prompt laser, ranibizumab ? deferred laser, tri-
amcinolone ? laser, and sham ? laser groups
were ?9, ?9, ?4, and ?3 letters, respectively.
Most of the gains in BCVA occurred by the 8--
week visit. During the first 3 months of the trial,
patients who were treated with triamci-
nolone ? laser experienced improvement in
BCVA that were similar to those receiving
ranibizumab. However, BCVA in the triamci-
nolone group worsened over the subsequent
9 months because of the development of corti-
costeroid-induced cataracts. On the other hand,
patients in the triamcinolone/laser group who
were pseudophakic at baseline experienced 1--
year improvement in BCVA comparable to that
in the ranibizumab arms. The following
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subgroup analyses found no significant differ-
ences in 1-year visual acuity outcomes: prior
treatment for DME, baseline visual acuity,
baseline CST, and baseline severity of DR.
Improvements in CST were comparable in the
groups receiving ranibizumab and triamci-
nolone, all of which exceeded those in the
group receiving sham/laser. Eyes treated with
ranibizumab were less likely to experience
increases in DRSS.
During the second year of the trial, the
interval between examinations could be exten-
ded to 8 weeks if treatment had been deferred
for two consecutive visits, and to 16 weeks if
treatment was not performed at the 8-week
visit. Patients in the triamcinolone/laser and
laser/sham groups were eligible to receive rani-
bizumab as early as week 74 for persistent
edema without improved BCVA. The 2-year
BCVA outcomes were similar to those at 1 year,
in that 44–49% of ranibizumab-treated eyes
improved by at least ?10 letters and 28–29%
improved by at least ?15 letters [45]. Compared
to the sham/laser group, the mean changes in
BCVA in patients receiving ranibizumab ?
prompt laser, ranibizumab ? deferred laser, and
triamcinolone ? prompt laser were ?3.7, ?5.8,
and -1.5 letters. Within the first 2 years of the
trial, 43 eyes in the sham/laser group were
switched to ranibizumab because of treatment
‘‘failure,’’ whereas only one of the patients ran-
domized to ranibizumab required switching.
At the 3-year visit, the median numbers of
injections given to patients in the
ranibizumab ? prompt laser and ranibizumab ?
deferred laser groups were 12 and 15, respec-
tively [46], and the median numbers of laser
treatments were 3 and 0, respectively. Only 46%
of patients in the ranibizumab ? deferred laser
group had been treated with laser. Patients
randomized to ranibizumab ? deferred laser
had BCVA improvements that were ?2.9 letters
greater than those randomized to
ranibizumab ? prompt laser (P = 0.02). The
proportions of eyes with CST C250 lm were
36% in each of the ranibizumab arms.
At the 5-year visit, the mean BCVA
improvements from baseline were ?7.2 letters
in the ranibizumab ? prompt laser group and
?9.8 letters in the ranibizumab ? deferred laser
group (P = 0.09) [47]. Visual acuity loss of C10
letters was experienced by 9% and 8% of
patients, improvement of C10 letters by 46%
and 58%, and improvement of C15 letters by
27% and 38%, respectively. Only 44% of
patients who were randomized to
ranibizumab ? deferred laser received laser
photocoagulation through 5 years. The median
numbers of ranibizumab injections adminis-
tered during the trial were 13 and 17, 54% and
45% of patients did not receive ranibizumab
during year 4, and 62% and 52% did not receive
ranibizumab during year 5.
RETAIN
The previously discussed trials demonstrated
the efficacy of both monthly and PRN therapy
for DME, but most physicians treat chorioreti-
nal vascular conditions according to a
treat-and-extend (T&E) regimen. The RETAIN
trial randomized 372 patients to receive T&E
0.5 mg ranibizumab ? laser (G1), T&E 0.5 mg
ranibizumab (G2), or monthly PRN 0.5 mg
ranibizumab (G3) [48]. Patients received
monthly injections until BCVA stabilized, after
which patients in G1 and G2 could be extended
at 1-month intervals up to a maximum of
3 months. At the 24-month endpoint, median
BCVA changes in the G1, G2, and G3 groups
were ?8.3, ?6.5, and ?8.1 letters, respectively.
Seventy percent of patients receiving T&E were
extended to a treatment interval of at least
2 months, and they required 40% fewer clinic
visits than those receiving PRN injections.
COMPARISON STUDIES
Few prospective randomized DME trials have
directly compared ranibizumab with beva-
cizumab and aflibercept. A 48-week randomized
prospective trial compared bevacizumab with
ranibizumab in 45 patients with DME [49].
BCVA improved significantly in both groups at
all visits (P\0.05), but those receiving ranibi-
zumab experienced greater increases at weeks 8
(P = 0.0318) and 32 (P = 0.0415). Patients
receiving bevacizumab required more injections
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than those receiving ranibizumab (means 9.84
vs. 7.67).
The prospective randomized multi-center
DRCR.net Protocol T trial was the only trial to
directly compare all three anti-VEGF drugs [50].
Six hundred sixty patients at 89 sites received
1.25 mg bevacizumab, 0.3 mg ranibizumab, or
2 mg aflibercept. Patients were treated accord-
ing to a complicated algorithm that featured
monthly injections until BCVA and CST were
stable, and laser photocoagulation at 24 weeks
for persistent edema.
The median numbers of injections through
52 weeks were nine (aflibercept), ten (beva-
cizumab), and ten (ranibizumab) (P = 0.045 for
overall comparison), and laser photocoagula-
tion was performed in 37%, 56%, and 46% of
eyes, respectively (P\0.001). Mean changes in
BCVA were ?13.3 letters (aflibercept), ?9.7 let-
ters (bevacizumab), and ?11.2 letters (ranibi-
zumab). A pre-planned subgroup analysis found
that for eyes with baseline BCVA of 20/32 to
20/40, mean BCVA changes were ?8.0 (afliber-
cept), ?7.5 (bevacizumab), and ?8.3 letters
(ranibizumab). For eyes with baseline visual
acuity of B20/50, mean changes in BCVA were
?18.9 (aflibercept), ?11.8 (bevacizumab), and
?14.2 letters (ranibizumab), and the average
changes in CST were -169 lm, -101 lm, and
-147 lm.
The differences in BCVA improvements
among the drugs had narrowed by 2 years and
were no longer statistically significant for
aflibercept vs. ranibizumab [51]. Mean
improvements in BCVA for patients receiving
aflibercept, bevacizumab, and ranibizumab
were ?12.8, ?10.0, and ?12.3 letters, and were
?18.1, ?13.3, and ?16.1 letters in patients with
baseline acuity of 20/50 or worse (aflibercept vs.
ranibizumab, P = 0.18; ranibizumab vs. beva-
cizumab, P = 0.18). The median numbers of
injections were 15, 16, and 15 (global: P = 0.08),
and laser photocoagulation was performed in
41%, 64%, and 52% of patients.
Up to 40% of patients receiving ranibizumab
injections experience a suboptimal response to
therapy, with persistent macular edema [52].
Some authors recommend that these patients
receive laser photocoagulation, intraocular cor-
ticosteroids, or a different anti-VEGF drug, but
since randomized controlled trials have not
adequately addressed this, physicians have
insufficient guidance regarding the best strat-
egy. A post hoc analysis of the DRCR.net Pro-
tocol I data evaluated the effects of ‘‘switching’’
therapy in patients treated with ranibizumab
[53]. Switching rules were applied to patients at
the 3- and 6-month visits. Over the subsequent
3 months, these patients experienced improve-
ment in BCVA of three to five letters and CST of
-40 to -70 lm. The authors point out the need
for comparison groups, since improvement
with switching may be confused with delayed
improvement from ranibizumab therapy.
PROLIFERATIVE DIABETIC
RETINOPATHY
In addition to restoring the integrity of the
blood–retinal barrier and enabling resorption of
macular edema, ranibizumab possesses potent
anti-angiogenic activity. Ranibizumab has been
used as monotherapy and in combination with
panretinal photocoagulation to treat PDR.
Retinal neovascularization rapidly involutes
after ranibizumab injections, but these effects
are usually transient, and pan-retinal photoco-
agulation (PRP) may still be necessary to per-
manently close new vessels.
Ranibizumab combined with PRP was com-
pared to PRP alone for the treatment of high--
risk PDR in 40 patients [54]. Split-session PRP
was performed in all eyes at baseline and week
2, and 0.5 mg ranibizumab was given to the
‘‘PRP Plus’’ group at the completion of the first
laser session and again at weeks 16 and 32 if
needed. Patients were evaluated with ETDRS
BCVA measurements, fluorescein angiography
(FA), and OCT. Significant reductions in FA
leakage were seen at all visits though 48 weeks
in both groups, but the reduction was signifi-
cantly greater in the PRP Plus group. BCVA
worsened in the laser monotherapy group at 16,
32, and 48 weeks, but was unchanged in the
PRP Plus group. The CST increased at all visits in
the laser group but decreased at week 16 and
stabilized through week 48 in the PRP Plus
group. The authors concluded that the addition
of ranibizumab to PRP reduces PDR-related FA
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leakage, and improves visual acuity and central
macular thickness.
The DRCR.net Protocol S trial randomized
305 patients at 55 sites to receive panretinal
photocoagulation or intravitreal 0.5 mg ranibi-
zumab for PDR [55]. Complete photocoagula-
tion was performed at baseline, and
ranibizumab was injected every 4 weeks
through 12 weeks, at weeks 16 and 20 if neo-
vascularization persisted, and then monthly at
the discretion of the investigator. All eyes with
DME were eligible to receive ranibizumab. The
primary outcome was change in BCVA and
secondary outcomes included visual acuity area
under the curve, peripheral visual field loss (as
measured on Humphrey automated visual field
testing), the need for vitrectomy, development
of DME, and persistent or new neovasculariza-
tion. Improvements in BCVA for the ranibizu-
mab and PRP groups were ?2.8 and ?0.2 letters
respectively (95% CI, -0.5 to ?5.0). The rani-
bizumab group experienced less peripheral
visual field sensitivity loss (-23 vs. -422 dB;
95% CI, 213–531 dB; P\0.001), required fewer
vitrectomy procedures (4% vs. 15%; 95% CI
4–15%; P\0.001) and were less likely to
develop DME (9% vs. 28%). For eyes without
DME at baseline, a median of 7 ranibizumab
injections were administered through year 1
and ten injections through year two. Forty-five
percent of PRP eyes required additional laser
and 35% of eyes in the PRP group received
ranibizumab at baseline for DME and an addi-
tional 18% received ranibizumab because they
developed DME during the 2 year trial.
SAFETY
Approximately 1% of ranibizumab has an
excellent safety profile with low incidence of
both ocular and systemic adverse events.
Approximately 2% of patients in the RESOLVE
and Protocol I trials developed endophthalmitis
[40, 46] but incidence has subsequently fallen as
physicians have become more proficient at
delivering injections.
Patients with diabetesmellitus are at high risk
of cardiovascular embolic events so adverse event
rates must be viewed in the correct context. In
the RESOLVE trial, the incidence rates of hyper-
tension and arterial thromboembolic events
were similar in the ranibizumaband shamgroups
[40]. By 3 years, the rates of Antiplatelet Trialists’
Collaboration (APTC)-related events in the
sham/laser, 0.3-mg ranibizumab, and 0.5-mg
ranibizumab groups were 7.2%, 10.8%, and
10.4%, and the overall rates of death were 2.8%,
4.4%, and 6.4% [38]. In the Protocol T trial, APTC
events were seen in 5% of patients receiving
aflibercept, 8% receiving bevacizumab, and 12%
receiving ranibizumab (global P = 0.047) [50].
These resultsmust be contrastedwith those from
READ-2, Protocol I, and RESTORE, in which the
incidence of APTC events in ranibizumab groups
did not differ significantly from that in laser--
treated patients. In aggregate, the incidence of
serious systemic adverse events in patients trea-
ted with ranibizumab varies among trials, but
does not appear to differ markedly from that
associated with other anti-VEGF drugs.
DISCUSSION
Several published trials have produced level I
evidence showing that ranibizumab is superior
to laser photocoagulation for the treatment of
DME. Ranibizumab has thus emerged as an
excellent first-line therapy for DME, either as
monotherapy or in combination with laser
photocoagulation of the macula. Initial inten-
sive therapy (monthly injections) appear to
produce the best short-term and long-term
results. Following initial resolution of the mac-
ular edema, physicians have the discretion to
continue monthly therapy, treat recurrent
edema as needed, or pursue a treat-and-extend
strategy. Fortunately, excellent long-term
results have been reported with each strategy.
Following initial ranibizumab therapy,
severity of the retinopathy frequently improves
and the need for frequent injections lessens.
Nonetheless, patient compliance remains criti-
cal to the delivery of effective therapy, and
patients benefit when physicians carefully out-
line both the short-term and long-term strate-
gies when initiating ranibizumab therapy.
Despite the best efforts of physicians and
their staff, treatment of patients may be
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insufficient for several reasons. Many patients
in both industrialized and developing nations
have insufficient resources to cover the long--
term costs incurred for the treatment of DME.
This may be due to excessive travel costs to the
physician’s office, insufficient health care
insurance to pay for professional services, or
inadequate access to effective drugs. As a result,
many patients are unable to see physicians in a
timely manner, are able to be diagnosed but
cannot afford treatment, or are able to receive
only a limited number of intravitreal injections
that are insufficient for permanently resolving
DME. Because the number of patients with DME
in most nations will continue to grow, these
inadequacies in health care delivery are not
likely to be easily remedied.
In addition to center-involving DME, rani-
bizumab has also been approved for the treat-
ment of diabetic retinopathy in eyes with
non-center-involving DME. Treating these eyes
may prevent or delay vision loss, but most
physicians wait for the development of cen-
ter-involving DME or PDR before initiating
ranibizumab therapy.
Ranibizumab may be a reasonable alternative
to PRP for the treatment of PDR. Ranibizu-
mab-treated patients experience less DME and
require fewer vitrectomy procedures, but com-
pliance is critical for the prevention of severe
vision loss. The efficacy of this strategy has not
been determined beyond 2 years.
CONCLUSION
Ranibizumab is an effective and safe first-line
therapy for the treatment of DME. It may pro-
vide advantages over PRP for the treatment of
PDR, but patient selection is important.
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